<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Serum soluble transferrin receptor (sTfR) has been reported to be higher in patients with <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e> or with elevated erythropoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, serum sTfR was measured in various anemic diseases and their clinical significance was examined in a multi-institutional joint study </plain></SENT>
<SENT sid="2" pm="."><plain>Serum sTfRs in patients with the following anemic diseases were markedly higher than those in <z:mpath ids='MPATH_458'>normal</z:mpath> healthy adults: non-treated <z:hpo ids='HP_0001891'>iron deficiency anemia</z:hpo> (IDA) (9.13 +/- 7.04 mg/l, n = 52, p &lt; 0.0001), <z:hpo ids='HP_0001903'>anemia</z:hpo> of <z:hpo ids='HP_0011010'>chronic</z:hpo> disorders (ACD) (3.45 +/- 1.38 mg/l, n = 20, p &lt; 0.0001), <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> (HA) (5.57 +/- 3.26 mg/l, n = 17, p &lt; 0.0001), and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (4.03 +/- 2.83 mg/l, n = 20, p &lt; 0.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>There were significant differences between IDA and ACD (p &lt; 0.0001), between <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) (1.58 +/- 1.26 mg/l, n = 16) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (p &lt; 0.001), and between AA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA) (4.16 +/- 3.40 mg/l, n = 9) (p &lt; 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> (CRF), serum sTfR levels and serum sTfR/log serum ferritin ratios (sTfR/F index) were compared in the two classified groups according to Muirhead's criteria, as IDA and non-IDA groups with or without recombinant human erythropoietin (rHuEPO) treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Significantly high levels of both serum sTfR (p &lt; 0.0001) and the sTfR/F index (p &lt; 0.0001) were observed in IDA without rHuEPO treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Especially in CRF with rHuEPO treatment, the sTfR/F index showed marked elevation in the IDA group (p &lt; 0.0001) compared with serum sTfR (p &lt; 0.001), indicating more diagnostic efficacy of the sTfR/F index for CRF with IDA </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, the serum sTfR concentration is a useful diagnostic tool for discrimination between IDA and ACD, and between AA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA, and for the detection of <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e> in CRF patients in the Japanese population </plain></SENT>
</text></document>